Etamzilat in ampoules can be drunk. Etamzilat - instructions from the application, indications, side effects, analogues and price. Indications and contraindications

Etamzilat (amp. 12.5% ​​-2ml N10)

Trade name Etamzilat retail for injections 12.5%
Registration number 84/329/8
Date of registration 27.03.1984
Cancellation date
Virobnik ~ - Russia

Packaging:
No. Packing ID EAN
1 type for intravenous and intravenous administration 125 mg/ml 2 ml, ampoules (10) - packs of cardboard FS 42-2807-98 ~
2 types for intravenous and intravenous administration 125 mg/ml 2 ml, ampoules (5) - compact contour packs (1) - packs of cardboard FS 42-2807-98 ~
3 varieties for intravenous and intravenous administration 125 mg/ml 2 ml, ampoules (5) - packs of compact contours (2) - packs of cardboard FS 42-2807-98 ~
INN
Etamzilat
Pharmaceutical form
rozchin for injections
Chemical name
2, 5 - dihydroxybenzenesulfonic acid with diethylamine

Pharmacological activity

Hemostatic zasib; may also angioprotective and proaggregant diyu. Stimulation of platelets and their release from the cystic brain. It is hemostatic, stimulates the activation of formation of thromboplastin in the musculoskeletal system of other vessels and decreases in the incorporation of prostacyclin PgI2 in the endothelium of the vessels, promotes the adhesion and aggregation of platelets, and can lead to hemorrhage in the endothelium.

Increased speed of elimination of the primary thrombus and potentiates yogo retraction, practically does not affect the concentration of fibrinogen and the prothrombin hour. Doses greater than 2-10 mg/kg do not produce a greater effect. With repeated attacks, thrombus formation becomes stronger.

Mayuchi antihyaluronidase activity and stabilizing ascorbic acid, pereskodzhaє ruynuvannyu and spryaє utavlennyu in the walls of the capillaries of mucopolіsaccharides with a great molecular mass, increasing the resistance of the capillaries, reducing their frizziness, normalizing the penetration in pathological processes.

Changes in the flow of blood and diapedesis of the form of blood elements from the vascular bed, improving microcirculation.

Do not have hypercoagulable powers, do not spread thrombosis, do not have vessel-sounding activity.

Revealing pathological changes in the hour of bleeding. On normal parameters, hemostasis does not penetrate.

The hemostatic effect with intravenous administration of etamsylate persists after 5-15 minutes, the maximum effect is manifested after 1-2 years. Diya three stretches for 4-6 years, then stretches for 24 years progressively weaker; with an internal introduction, the effect is worse. When taken internally, the maximum effect is observed in 2-4 years. After the exchange rate, the effect is taken with a stretch of 5-8 decibels, progressively weaker.
Pharmacokinetics

The good is absorbed like with an internal injection, so if I take it internally. Therapeutic concentration in the blood is 0.05-0.02 mg/ml. Progressively rozpodіlyaєtsya in various organs and tissues (deposit at the stage of their bleeding). Weakly zv'yazuєtsya with proteins and forms of blood elements. Shvidko is taken from the body, the head rank - nirkami (for the unchangeable look), and also from Zhovchyu. T1 / 2 after internal introduction - 2.1 years, after internal - 1.9 years. After 5 minutes after intravenous injection, nirks show 20-30% of the administered drug, and again after 4 years.
Indication before zastosuvannya

Prevention of this type of bleeding: parenchymatous and capillary bleeding (including traumatic, in surgery during operations on highly vascularized organs and tissues, during surgical interventions in dental, urological, ophthalmological, otolaryngological practice, and menorrhagia). secondary bleeding on the background of thrombocytopenia and thrombocytopathy, hypocoagulation, hematuria, intracranial hemorrhage (including in newborns and premature babies), nasal bleeding on the background of arterial hypertension, lytic diathesis ), diabetic microangiopathy (hemorrhagic diabetic retinopathy, repeated bleeding in the sitkivka, hemophthalmos).
Contraindication

Hypersensitivity, thrombosis, thromboembolism, gostra porphyria.
For protection

With bleeding and natomist overdose of anticoagulants.
Dosing mode

In / in, in / m that inside. In ophthalmological practice - in the sight of ophthalmic streaks and retrobulbar.

The intravenous dose for adults is 0.25-0.5 g, if necessary, it can be reduced to 0.75 g; parenterally - 0.125-0.25 g, if necessary, increase to 0.375 g.

We grow up: in case of operative insertion prophylactically - internally or internally 1 year before surgery - 0.25-0.5 g or internally, directly in front of the receptionist, 3 years before surgery - 0.5-0.75 g. If necessary - 0.25-0.5 days internally hour of operation and prophylactically - 0.5-0.75 g intravenously, internally or 1.5-2 g intravenously, evenly stretching doby - after the operation.

In case of intestinal, legenevyh bleeding - internally, 0.5 g for a stretch of 5-10 days, while continuing the course of treatment, the dose is reduced; with metro- and menorrhagia - the same doses during bleeding and 2 onset cycles.

With hemorrhagic diathesis, diseases of the blood system, diabetic angiopathies - in the middle, 0.75-1 g per doba, through equal intervals, in courses of 5-14 days.

For children: in case of surgical interventions, prophylactically - internally, 1-12 mg / kg for 2 doses for 3-5 days. If necessary, during the hour of surgery - intravenously, 8-10 mg/kg.

For early bleeding after surgery - internally, 8 mg / kg.

With hemorrhagic syndrome - at a single dose of 6-8 mg / kg intravenously, 3 times a day, in courses of 5-14 days; the course can be repeated for 7 days.

Hemorrhages in diabetic microangiopathies - intramuscularly, 0.25-0.5 g 3 times a day or 0.125 g 2 times a day for 2-3 months.

Rozchin for injections can be zastosovuvat mіstsevo (sterile tampon leak and impose on the wound).
Pobichna diya

Pechіya, heaviness in epigastric dilation, head bіl, zamorochennya, hyperemia of the upper limbs, decreased systolic arterial pressure, paresthesia of the lower limbs, allergic reactions.
Interaction

Pharmaceutical insane (in one syringe) s in. LZ.

Introduction at a dose of 10 mg/kg 1 year before dextran (average molecular weight 30-40 thousand Da) improves antiplatelet activity; introduction after no hemostatic effect.

You can take aminocaproic acid and menadione sodium bisulfite.
especially vkazіvki

Necessary care (regardless of the day of induction of thrombosis) in case of recognition of etamsylate ailment for thrombosis or thromboembolism in history.

With hemorrhagic complications associated with overdose of anticoagulants, it is recommended to use specific antidotes. The use of etamsylate in patients with impaired indications of the system of pharyngeal blood can, however, be supplemented with the introduction of LZ, which can cause symptoms of deficiency or a defect in factors of the pharyngeal system.

Formula: C10H17NO5S, chemical name: 2,5-Dihydroxybenzenesulfonic acid with diethylamine.
Pharmacological group: organotropic diseases / cardiovascular diseases / angioprotective and corrective microcirculation; hematotropic diseases/coagulants (including factors of blood formation), hemostatics.
Pharmacological action: angioprotective, hemostatic.

Pharmacological authorities

Etamzilat stimulates the production of platelets and their release from the cystic brain. Etamzilat activating thromboplastin in the area of ​​susceptibility of other tissue vessels, adhering to platelet aggregation and adhesion, reducing bleeding. Etamzilat promotes the formation of the primary thrombus and potentiates retraction, while not adding to the level of PV and fibrinogen. With repeated victories, etamzilate thrombosis becomes stronger. Etamzilat determines the hour of bleeding, pathological changes. Etamzilat does not affect the normal parameters of the hemostasis system. Do not show vessel sound, do not call hypercoagulability. Stabilizing ascorbic acid and increasing anti-hyaluronidase activity, etamzilate pereskodzha decomposing mucopolysaccharides and adhering to their absorption in the walls of vessels with a large molecular weight, changing the cryogenic resistance of capillaries, with normal progression Etamzilat improves microcirculation, reduces diapedesis of the formation of blood elements and removal of blood from the vessel bed.

Etamzilat good vmoktuєtsya when taken internally and when administered internally. Etamzilat is equally distributed in various tissues and organs. Formed by blood elements and proteins, they are weakly connected. From the body to be introduced quickly to the unchangeable sight, most importantly nirkami, through the intestines - in small numbers. After 5 minutes, with intravenous administration of nirks, 20-30% of the drug is seen, after 4 years, etamsylate is excreted from the body completely. With the introduction of internally, after 5-15 minutes, activation of hemostasis begins, after 1-2 years it becomes maximum, stretching for 4-6 years is trimmed at a sufficient level and sticks to the end of the doby, progressively weak; with the introduction of internal lingual effects, things develop better. If taken internally, the maximum effect develops in 2-4 years. With course therapy, the effect is saved by 5-8 decibels, then progressively weaker.

Indication

Zupinka and prophylaxis of bleeding: capillary and parenchymal bleeding, including traumatic, in surgery for an hour of operations on tissues and organs, which are well treated, with surgical intervention in urological (prostatectomy and other), dental (extraction of teeth, type of tooth extraction) cataracts, keratoplasty, protiglaucomatous surgery and other surgical interventions), otolaryngological (microsurgical surgery on the ear, tonsillectomy and other) practice; menopause of metrorrhagia in fibromyoma; legenev, nirkov, intestinal bleeding; secondary bleeding in thrombocytopathy and thrombocytopenia; hematuria; hypocoagulation; nasal bleeding in case of arterial hypertension; intracranial hemorrhage (including in premature and new born children); medical bleeding (only stinks not caused by anticoagulants); hemorrhagic diathesis (including Willebrand-Jurgens, Werlhof, thrombocytopathy); hemorrhagic vasculitis; diabetic microangiopathy (repeated hemorrhage in the sitkivka, hemorrhagic diabetic retinopathy, hemophthalmos); ailments of the vessels with hemorrhagic syndrome.

How to inject etamsylate and doses.

Etamzilat is taken internally, administered internally, internally. Zalezhno according to the indication, the dosing regimen is set individually. For older adults, the average single dose is 250-500 mg (if necessary, you can increase up to 750 mg) 3-4 times per doba. Internally and internally - for mature adults, the optimal additional dose is 10 - 20 mg / kg, which is increased by 3 - 4 injections; for children, children - 10 - 15 mg / kg / dose for 3 - 4 doses. Rozchin for injections can be victoriously mixed, applied to the wound, leaking a sterile swab with the preparation. In ophthalmology, the vicorist is retrobulbar and subconjunctival in appearance of ophthalmic drops.
When vikoristan etamsylate in patients with thromboembolism or thrombosis in history, care is necessary. In case of hemorrhagic complications associated with overdose of anticoagulants, it is recommended to use specific antidotes. The use of etamsylate in ailments with impaired indications in the system of pharyngeal blood can, however, be due to additional administration of preparations, as it may cause manifestations of a defect or deficiency of factors in the pharyngeal system.

Contraindication to congestion

Hypersensitivity, gostra porphyria, thromboembolism, thrombosis, hemoblastosis in children.

Frozen until zastosuvannya

Hemorrhages under the hour of anticoagulants.

Congestion with vagity and breastfeeding

Vykoristanya etamzilat during the hour of vagity can only be more than once, if the melancholy for the mother is calculated for the potential risk for the fetus (the safety of etamzilatu during vagity is not installed). For an hour of therapy with etamzilate, it is necessary to take a breast lift.

Side effects of etamzilat

Confusion, hyperemia of the upper limbs, allergic reactions, cephalic pain, paresthesia of the lower limbs, liver, decreased systolic arterial vice, heaviness in epigastric dilatation.

Interaction of etamsylate with other speeches

Etamzilat with other drugs is pharmaceutically insane (in one syringe). Permissible use of etamsylate with menadione sodium bisulfite, aminocaproic acid. Administering etamsylate 1 year prior to dextran at a dose of 10 mg/kg will prevent its (dextran) antiaggregation activity (administration of etamsylate after dextran will not reverse the hemostatic effect).

INSTRUCTIONS
from the medical prescription of the drug

Registration number:

P N013946/02

Trade name of the drug:

Dicynon

International non-proprietary name:

etamzilat

Pharmaceutical form:

Rozchin for internal and external introduction.

Stock:

Skin 2 ml (1 ampoule) for intravenous and intravenous administration:
Active speeches: etamzilat 250 mg.
Additional speeches: sodium disulfite 0.84 mg, water for injection up to 2 ml, sodium bicarbonate for pH correction.

Description:
Prozory bezbarvny rozchin.

Pharmacotherapeutic group:

Hemostatic zasib.

CodeATX: B02BX01

Pharmacological authorities:

Pharmacodynamics
Etamzilat is a hemostatic, antihemorrhagic and angioprotective method, normalizes the penetration of the vessel wall, improves microcirculation. Stimulation of platelets and their release from the cystic brain. Promoting platelet adhesion, stabilizing the walls of capillaries, thereby reducing their penetration, galvanic synthesis of prostaglandins, which leads to platelet disaggregation, vasodilatation and increased capillary penetration, which shortens the bleeding time. Increased speed of elimination of the primary thrombus and potentiates retraction, practically does not affect the concentration of fibrinogen in blood plasma and the prothrombin hour.
With repeated stosuvanni, thrombosis becomes stronger.
Etamzilat practically does not penetrate into the storage of peripheral blood, proteins and lipoproteins. The speed of erythrocyte sedimentation may change a little. Changes in the flow of blood and diapedesis of the form of blood elements from the vascular bed, improving microcirculation. Do not repair the ship's sound system.
Mayuchi antihyaluronidase activity and stabilizing ascorbic acid, reversing the collapse and adhering to the capillary walls of mucopolysaccharides with a large molecular weight, increasing the resistance of capillaries, reducing the penetration of cracking, normal. Tsya angioprotective action is manifested in the treatment of various diseases associated with primary and secondary disorders of the microcirculation process.

Pharmacokinetics
hemostatic effect in internal zastosuvannya The rise of etamzilat occurs after 5-15 minutes, the maximum effect is after 1-2 years. Diya continues with a stretch of 4-6 years, then with a stretch of 24 years, progressively weaker. With intravenous injection, the hemostatic effect persists after 30-60 minutes.
After intravenous/intrinsic administration of 500 mg of etamsylate, the maximum plasma concentration is reached after 10 minutes and becomes 30-50 mcg/ml.
Mayzhe povnistyu penetrates through the placental barrier. It is not known how etamsylate penetrates mother's milk.
Close to 90% etamzilat binds to blood plasma proteins.
Etamzilat is slightly affected by metabolism.
Approximately 80% of the administered dose is excreted through the nipple in an unchanging way. The period of injection with plasma after intravenous administration becomes close to 2 years. Approximately 85% of administered doses of etamsylate were administered for 24 years.
No clinical studies have been conducted regarding the ingestion of etamsylate in patients with impaired liver function and/or studies.

Indication before zastosuvannya

Prevention and treatment of capillary bleeding of various etiology:

• before, pіd hour and after surgery on all good vascularized tissues in dentistry, otorhinolaryngology, gynecology, urology, ophthalmology, obstetrics and plastic surgery;
• hematuria, metrorhagia, primary menorrhagia, menorrhagia in women using intrauterine contraceptives, nasal bleeding, clear bleeding;
• diabetic microangiopathy (hemorrhagic diabetic retinopathy, repeated hemorrhage in the sitkivka, hemophthalmos);
• intracranial hemorrhage in newborns and premature babies.

Contraindication

• Contraindication. Increased sensitivity to drug components.
• Bronchial asthma, increased sensitivity to sodium sulfite
• Gostra porphyria.
• Hemoblastosis in children (lymphoblastic and myeloblastic leukemia, osteosarcoma).
• Thromboembolism, thrombosis.

For protection
Thrombosis; thromboembolism in history; bleeding due to an overdose of anticoagulants

Zastosuvannya with vagity and during lactation
Daily clinical data on the possibility of using the drug Dicynon in female women. Zastosuvannya Dicinon under the hour of vagity can be less in that moment, as the mother's greed is transferred to the mother's potential risk for the fetus.
When the drug is prescribed during lactation, there should be a change in nutrition when breastfeeding.

Method of stosuvannya that dose

Internally, internally.
The optimal supplementary dose of etamzilat for adults is 10-20 mg/kg of body weight per doba, divided into 3-4 doses, in case of an internal or general internal injection.
Doroslim
In case of surgical interventions, it is prophylactic to administer intravenously or intraperitoneally 250-500 mg (1-2 ampoules) intravenously or 1 year before the intravenous operation. Under the hour of surgery, intravenously inject 250-500 mg (1-2 ampoules) of etamzilat, if necessary, the dose can be repeated once more. After the operation, inject 250-500 mg (1-2 ampoules) into the skin for 4-6 years until the risk of bleeding occurs.
For bleeding problems, administer intravenously or intravenously 250-500 mg (1-2 ampoules), after which the skin is 4-6 years old, 250 mg for 5-10 days.
In case of treatment, the menorrhagic drug is administered at a single dose of 250 mg intravenously or intradermally for 6-8 years for 5-10 days.
In diabetic microangiopathies, the drug is administered subconjunctivally or retrobulbarno at a dose of 125 mg (1/2 ampoule). The drug Dicinon can be zastosovuvaty mistsevo (for example, in a different skin graft, after the tooth is pulled out thinly): a sterile tampon or a servlet is leaked out and applied to the wound.
Children Dosage for adults must be changed by 50%.
At neonatology the drug Dicinon is administered internally at a dose of 10 mg per kg of body weight (0.1 ml = 12.5 mg). Lіkuvannya next rozpochati for the first 2 years after the people, then the skin for 6 years for 4 days.
As the drug Dicinon is mixed with 0.9% sodium chloride, it should not be congested. Pobichna diya

Pobichna diya

According to the data of the All-World Organization for Health Protection (WHO), non-bazhanie effects are classified according to their frequency development by an offensive rank: often (> 1/100,<1/10), нечасто (>1/1000, <1/100), редко (>1/10000, <1/1000) и очень редко (<1/10000), включая отдельные сообщения.
From the side of the grass system
often: boredom, heaviness in epigastric dilation.
From the side of the shkіri and pіdshkіrnih fabrics
often: hanging on a shkіrі;
frequency of non-home: hyperemia shkiri guise
From the side of the nervous system
often: head bіl;
frequency of non-home: zamorochennya, paresthesia of the lower limbs
From the side of the cardiovascular system
very rarely: Thromboembolism, pronounced decrease in arterial pressure
From the side of the blood system and lymphatic system
very rarely: agranulocytosis, neutropenia, thrombocytopenia.
To the side of the musculoskeletal apparatus
rarely: arthralgia.
From the side of the immune system
very rarely: Allergic reactions.
Other
often: asthenia;
very rarely: fever.

Overdose

Up to this hour, no symptoms of overdose have been described.
If an overdose is necessary, symptomatic therapy is necessary.

Interaction with other medical care
Pharmaceutical insane (in one syringe) with other medical procedures.
Designed for injections Dicynon is insane from sodium bicarbonate for injections and sodium lactate. Introduction at a dose of 10 mg / kg 1 year before dextran (average molecular weight 30-40 thousand Da) is superior to antiplatelet.
Dia: the introduction of the following does not have a hemostatic effect.
You can take aminocaproic acid and menadione sodium bisulfite.
Thiamin (vitamin B1) is inactivated by sodium sulfite, which should be included in the warehouse of Dicinon.

especially vkazіvki

For zastosuvannya less at likarnyah and polyclinics.
Before the spadix, turn off other causes of bleeding. With the appearance of farbuvannya, it is impossible to stop the growth of yoga.
The drug is not effective in patients with thrombocytopenia. With hemorrhagic complications associated with overdose of anticoagulants, it is recommended to use specific antidotes.
The use of the drug Dicynon in patients with impaired indications of the blood glottis system is possible, but it can be supplemented with the introduction of drugs, which may cause deficiency symptoms or a defect in the factors of the blood glottis system. Due to the rise in the risk of hypotension (pronounced decrease in arterial pressure) with the parenteral method of ingestion of the drug Dicynon, it can be saved in patients with unstable arterial pressure or succumbing to hypotension.
Razchin for injectable Dicynon in its warehouse contains sodium sulfite as an antioxidant, which can cause allergic reactions, nudota, diarrhea in patients with increased sensitivity to new. Allergic reactions can be pronounced and manifest as anaphylactic shock and / or life-threatening attacks of the poison. The frequency of the population is unknown, such a pathological reaction is more often observed in patients with bronchial asthma. In case of a guilty allergic reaction, the drug Dicynon can be ingested in a negligent manner. There have been no clinical studies on the ingestion of the drug Dicynon in patients with impaired liver function and diseases, so we should be careful with the ingestion of etamsylate in this category of patients.
There is no need for special foreign visits in case of low levels of non-vicerous medicinal preparation.

Injected into the building to the concentration of respect
No special guards needed.

Release form

Rozchin for intravenous and intravenous administration of 125 mg/ml, 2 ml of the drug in an ampoule from a flask-free neutral fold with a break point of a red color. On the upper part of the ampoule there is a ring of blue color.
5 or 10 ampoules in a blister, 2 or 5 blisters in a carton pack at once with instructions from zastosuvannya.

Wash away the savings

Take care at a temperature not higher than 25 ° C, in a protected view of light.
Take care of the place inaccessible to children.

The term of appurtenance

5 years.
Do not stop after the completion of the term of applicability.

Wash your permits from pharmacies

For a prescription.

Virobnik

Lek d.d., Verovshkova 57, 1526 Ljubljana, Slovenia.

Claims of the nadsilaty
At ZAT "Sandoz"
123317, Moscow, Presnenskaya emb., B. 8, building 1

Virobnik: BAT "Biohimik" Republic of Mordovia

ATC code: B02BX01

Farm group:

Release form: Rіdkі lіkarskі forms. Rozchin for injections.

Zagalnі characteristics. Stock:

Fluid speech: 125 mg etamsylate.

Additional speech: sodium sulfuric acid pyro (sodium disulfite), sodium sulfuric acid anhydrous (sodium sulfite), disodium salt of ethylenediamine, tetraoctic acid (Trilon B) (edetate disodium), water for injection.

Etamzilat is a hemostatic drug.

Pharmacological authorities:

Pharmacodynamics. Krovospinna dia is based on a strong interplay between endothelium and platelets. Promoting platelet adhesion, stabilizing the walls of capillaries, thereby reducing their penetration, galvanic synthesis of prostaglandins, which leads to platelet disaggregation, vasodilation and increased capillary penetration, which shortens blood flow. Increased speed of elimination of the primary thrombus and potentiates its retraction, practically does not affect the fibrinogen level and the prothrombin hour. Revealing pathological changes in the hour of bleeding. On normal parameters, hemostasis does not penetrate. The hemostatic effect with intravenous injection of Etamzilat occurs after 5-15 minutes, the maximum effect - after 1-2 years, lasts 4-6 years. With intravenous injection, the hemostatic effect persists after 30-60 minutes

Pharmacokinetics. The drug is well absorbed when administered internally, binds weakly to plasma proteins and forms of blood elements. Etamzilat is equally distributed in various organs and tissues (deposit at the stage of their bleeding). The period of administration of the drug after intravenous administration becomes 1.9 years, after intravenous administration - 2.1 years. After 5 minutes after intravenous administration, 20-30% of the administered drug is seen with nirks, and again - after 4 years. The effective concentration in the blood is 0.05-0.02 mg/ml. The drug is administered to the body as a smut rank from the section, in a small number from the zhovchyu.

Indication before zastosuvannya:

Capillary bleeding of various etiologies, especially as a result of viklikana bleeding of the ear endothelium: prevention of this tooth bleeding at the frequency and after surgical operations on well-vascularized tissues in otolaryngology, gynecology, obstetrics, urology, ophthalmology, dentistry; prevention and treatment of capillary bleeding of various etiology and localization: metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, nasal bleeding,.

Important! Let's get to know the exuberance

Method of stosuvannya that dose:

Etamzilat is administered intravenously, intraperitoneally, subconjunctivally and retrobulbarly in ophthalmology. Etamzilat can be administered intravenously dropwise in 5% glucose solution or in isotonic sodium chloride solution.

Doroslim: with a prophylactic method for surgical insertion, the drug is administered intravenously or internally 1 year before surgery 0.25-0.5 g (2-4 ml 12.5% ​​difference), if necessary, at a dose of 0, 25-0.5 g (2-4 ml 12.5% ​​difference), in case of unsafe postoperative bleeding - 0.5-0.75 g (4-6 ml 12.5% ​​difference)

Children: if necessary, intraoperatively. Etamzilat is administered intravenously in the rosary at a dose of 8-10 mg/kg body weight. For bleeding problems, Etamzilat should be administered intravenously or intraperitoneally 0.25-0.5 g (2-4 ml 12.5% ​​difference), after which the skin is 4-6 years old, 0.25 g each (2 ml 12.5% ​​difference). ) with a stretch of 5-10 days.

In case of treatment of metrot - menorrhagia, Etamzilat is prescribed at a single dose of 0.25 g (2 ml of 12.5% ​​solution) internally or internally to the skin for 6-8 years for 5-10 days.

In case of diabetic miacroangiopathies, Etamzilat should be administered internally for 10-14 days at a single dose of 0.25-0.5 g of trich per doba.

In ophthalmology, Etamzilat should be administered subconjunctivally or retrobulbarno - at a dose of 0.125 g (1 ml of 12.5% ​​difference).

Features of zastosuvannya:

It is necessary to be careful with patients, for those who, if necessary, should be careful or not.

The drug is not effective in patients with a decrease in the number of platelets. With hemorrhagic complications associated with overdose of anticoagulants, it is recommended to use specific antidotes.

The use of etamsylate in patients with impaired indications of the system of laryngeal blood is possible, but it can be supplemented with the introduction of drugs that cause deficiency symptoms or a defect in factors of the laryngeal system.

Bezpeka zastosuvannya etamzilat at vagіtnostі not installed. Etamzilat should zastosovuvaty pіd hіt vagіtnostі іlki іtіlki іt vypadkakh, yakshcho potenciyna melancholy for mіsіє outweighing the potential risk for the fetus. Next, sing the breast to the vigodovuvannya pіd hour of the mother's rejoicing with Etamazilat.

Pobichna diya:

Head white, blackened appearance, allergic visip, lower endings, decreased arterial pressure.

Interaction with other medical care:

It is not possible to mix etamzilat with other medical precautions. The introduction of the drug at a dose of 10 mg/kg body weight 1 year prior to the introduction of dextran distribution with an average molecular weight of 30,000-40,000 Da in order to avoid antiaggregation effects; the introduction of etamsylate after the distribution of dextran does not cause hemostatic activity. It is possible to take Egamsylate with aminocaproic acid and menadione sodium bisulfite.

Contraindication:

Gostra, hemoblastosis in children, increased sensitivity to any ingredient in the drug; thrombosis; thromboembolism.

With care - in case of bleeding against the background of an overdose of anticoagulants, vaginess.

Wash the savings:

The term of appurtenance up to 4 years. After the completion of the term of applicability, do not stop dry, protected from light at a temperature not higher than 25 °C. In a place inaccessible to children.

Wash the permits:

For the recipe

Package:

Rozchin for intravenous and intravenous administration 125 mg/ml. 2 ml ampoules. 5 ampoules are placed at the contour pack. 1, 2 contour packs are placed in a pack of cardboard. 10 ampoules per pack per carton. A pack is glued with a label - a parcel roll with a paper with a label or a cred. At the skin pack, they put instructions from zastosuvannya, lower ampoule or ceramic ampoule scarifier. When vikoristanny ampoules with notches, dots or rings, ampoules are not inserted.

Registration number: LP 002436-031014
Trade name of the drug: Etamzilat
International non-proprietary name: etamzilat
Pharmaceutical form: rozchin for internal and internal introduction
Warehouse for 1ml:
Active speech: etamzilat - 125.0 mg.
Additional speeches: sodium disulfite - 4.0 mg, disodium edatate - 0.1 mg, water for injections - up to 1 ml.
Description: the prozora is barren or the motherland is weakly barred.
Pharmacotherapeutic group: hemostatic zasib.
ATX code: B02BX01

Pharmacological authorities

Pharmacodynamics
The drug improves the capillary walls of mucopolysaccharides of the great molecular mass and increases the stability of capillaries, normalizes their penetration in pathological processes, improves microcirculation; may be hemostatic. The hemostatic effect of the activation of thromboplastin formation in the musculoskeletal cavity of the other vessels. The drug stimulates the establishment of factor III of blood pharynx, normalizes platelet adhesion. The drug does not affect the fibrinogen level and the prothrombin hour, does not have hypercoagulable powers and does not contaminate thrombi (blood clots).
Pharmacokinetics
After the internal introduction of etamzilat, it starts with a stretch of 5-15 quills. The maximum effect after 1:00 after the introduction of the dose. The drug is continued for 4-6 years. After administration of 500 mg, the maximum plasma concentration is reached after 10 minutes (50 µg/ml).
The period of injection with plasma after intravenous administration becomes close to 2 years. Etamzilat is equally distributed in various organs and tissues (deposit at the stage of their bleeding).
The drug is well absorbed when administered internally, binds weakly to plasma proteins and forms of blood elements. With intravenous injection, the hemostatic effect persists after 30-60 minutes. The period of administration with plasma after intravenous administration is 2.1 years
Penetrates through the placental barrier and mother's milk.
Approximately 72% of the administered dose is excreted through nicks during the first 24 years in an unchanging way.

Indication before zastosuvannya

Prevention and treatment of capillary bleeding of various etiology:
- every hour and after surgery on all good vascularized tissues in dentistry, otorhinolaryngology, gynecology, urology, ophthalmology, obstetrics and plastic surgery;
- hematuria, metrorhagia, primary menorrhagia, menorrhagia in women using intrauterine contraceptives, nasal bleeding, clear bleeding;
- diabetic microangiopathy (hemorrhagic diabetic retinopathy, repeated hemorrhage in the sitkivka, hemophthalmos);
- intracranial hemorrhages in newborns and premature babies.

Contraindication

Increased sensitivity to drug components
- Increased sensitivity to sodium bisulfite;
- gostra porphyria;
- hemoblastosis in children (lymphoblastic and myeloblastic leukemia);
- Thromboembolism, thrombosis;
- the period of breast growth.

With care: thrombosis; thromboembolism in history; bleeding on the background of an overdose of anticoagulants, vaginess

Stagnation in the period of pregnancy and in the period of breastfeeding

The teratogenic effect of etamzilat has not been detected in animal studies. In clinical studies, the fetotoxic effect of etamsylate was not suspected. However, due to the lack of clinical evidence, the stasis of etamsylate at the time of vagity is less likely in that case, as if the misfortune for the mother is transferred, the potential risk for the fetus is outweighed.
Data on the penetration of etamsylate into breast milk are daily. If the drug is recognized for a half hour of lactation, then breastfeeding should be prescribed.

Method of stosuvannya that dose

Internally, internally.
Etamzilat can be administered intravenously dropwise in 5% glucose solution or in isotonic sodium chloride solution.
The optimal supplementary dose of etamzilat for adults is 10-20 mg/kg of body weight per doba, divided into 3-4 doses, with either internal or general internal ingestion.
As etamzilat zmіshuyut іz fіzіologichnym razchiny, yogo trace vikoristovuvaty negajno.
We grow up: in case of operative interventions, it is prophylactic to administer intravenously or internally 250-500 mg 1 year before surgery, at the beginning of the operation, administer intravenously 250-500 mg, if necessary, this dose can be repeated once more. After surgery, administer 250-500 mg to the skin for 6 years until the risk of bleeding occurs.
Children: the additional dose should be 10-15 mg/kg body weight, divided into 3-4 doses.
In neonatology: etamsylate is administered intravenously or intravenously at a dose of 12.5 mg per kg body weight (0.1 ml = 12.5 mg). Jubilation followed by a stretch of the first 2 years after the people.
When treated with metromenorrhagia, the drug is prescribed at a single dose of 250 mg (2 ml of 12.5% ​​roz) intravenously or intradermally for 6-8 years for 5-10 days.
In case of diabetic microangiopathies, the drug is administered internally and lingually for 10-14 days at a single dose of 250-500 mg trichi per doba.

Pobichna diya

Allergic reactions, cephalic pain, congestion, paresthesia of the lower kinks, decreased arterial pressure in systole, hyperemia of the upper abdomen, tedium, liver, heaviness in the epigastric space, hyperthermia, upper limb hanging.

Overdose

About the overdoses of etamzilat overdose have not been mentioned before.

Interaction with other medical care

Etamzilat is pharmaceutically insane (in one syringe) with other medical procedures.
The use of etamzilate is inconsistent with the designation of sodium bicarbonate for injections and the designation of sodium lactate.
The introduction of the drug at a dose of 10 mg/kg body weight 1 year before the introduction of dextran formulations with an average molecular weight of 30,000-40,000, which will protect the antiplatelet disease of the rest; the introduction of etamsylate after the distribution of dextran does not cause hemostatic activity. It is possible to use etamsylate with aminocaproic acid and menadione sodium bisulfite.

especially vkazіvki

For zastosuvannya less in medical mortgages.
Before the spadix, turn off other causes of bleeding.
With the appearance of farbuvannya, it is impossible to stop the growth of yoga.
The drug can be applied locally (for example, in a different graft, after a tooth is pulled out thinly): a sterile swab or a servlet is leaked out and applied to the wound.
It is necessary to be careful in patients, in some cases, in some cases, thrombosis or thromboembolism has been observed. The drug is not effective in patients with a decrease in the number of platelets. With hemorrhagic complications associated with overdose of anticoagulants, it is recommended to use specific antidotes. The use of etamsylate in patients with impaired indications of the system of laryngeal blood is possible, but it can be supplemented with the introduction of drugs that cause deficiency symptoms or a defect in factors of the laryngeal system.
The drug is sodium bisulfite, which in single episodes can cause severe reactions, hypersensitivity (including anaphylactic shock) and bronchospasm.
At times, hyperthermia appeared, likuvannya next to come.

Injected into the building with a car and other working mechanisms
Etamzilat does not affect the building by car and other working mechanisms.

Release form
Rozchin for intravenous and intravenous administration 125 mg/ml. 2 ml in ampoules from a transparent flaskless fold (type I), a colored or white dot on the ampule is marked with a fracture; a label is glued on the skin ampoule, or a marking is applied with farboi, which is firmly fixed. 10 ampoules in a PVC blister, 1 or 5 blister at a time from the instructions from the packing in a pack of cardboard.

Wash away the savings
Protect the protected from light at a temperature not higher than 25 °C.
Take care of places inaccessible to children.